Skip to content

Praxis Precision Medicines

US · PRAX #1645 by market cap Listed 2020
300.43 -10.47 -3.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Praxis Precision Medicines

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Founded
2015
CEO
Mr. Marcio Souza
Employees
168
Headquarters
Boston, Massachusetts, United States of America
Fiscal year end
12-31
Website
praxismedicines.com

Company profile

Exchange
US
Symbol
PRAX
Market-cap rank
#1645
Listing date
2020-10-16
Market cap
8.40B
Float cap
7.24B
Shares out
27.95M
Float shares
24.11M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.

Praxis Precision Medicines discussion 0 comments

Add a comment